TY  - JOUR
AU  - Jančić, Ivan
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Kotur, Nikola
AU  - Klaassen, Kristel
AU  - Pavlović, Sonja
AU  - Bufan, Biljana
AU  - Arsenović-Ranin, Nevena
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2331
AB  - Background: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis
VL  - 34
IS  - 4
SP  - 414
EP  - 421
DO  - 10.2478/jomb-2014-0060
ER  - 

@article{
author = "Jančić, Ivan and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Kotur, Nikola and Klaassen, Kristel and Pavlović, Sonja and Bufan, Biljana and Arsenović-Ranin, Nevena",
year = "2015",
abstract = "Background: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis",
volume = "34",
number = "4",
pages = "414-421",
doi = "10.2478/jomb-2014-0060"
}

Jančić, I., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Kotur, N., Klaassen, K., Pavlović, S., Bufan, B.,& Arsenović-Ranin, N.. (2015). Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 34(4), 414-421.
https://doi.org/10.2478/jomb-2014-0060

Jančić I, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Kotur N, Klaassen K, Pavlović S, Bufan B, Arsenović-Ranin N. Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. in Journal of Medical Biochemistry. 2015;34(4):414-421.
doi:10.2478/jomb-2014-0060 .

Jančić, Ivan, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Kotur, Nikola, Klaassen, Kristel, Pavlović, Sonja, Bufan, Biljana, Arsenović-Ranin, Nevena, "Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis" in Journal of Medical Biochemistry, 34, no. 4 (2015):414-421,
https://doi.org/10.2478/jomb-2014-0060 . .

TY  - JOUR
AU  - Jančić, Ivan
AU  - Arsenović-Ranin, Nevena
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić, Sanja
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1998
AB  - To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.
PB  - Springer Heidelberg, Heidelberg
T2  - Rheumatology International
T1  - -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
VL  - 33
IS  - 6
SP  - 1481
EP  - 1486
DO  - 10.1007/s00296-012-2586-y
ER  - 

@article{
author = "Jančić, Ivan and Arsenović-Ranin, Nevena and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Srzentić, Sanja and Stanković, Biljana and Pavlović, Sonja",
year = "2013",
abstract = "To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Rheumatology International",
title = "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis",
volume = "33",
number = "6",
pages = "1481-1486",
doi = "10.1007/s00296-012-2586-y"
}

Jančić, I., Arsenović-Ranin, N., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić, S., Stanković, B.,& Pavlović, S.. (2013). -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International
Springer Heidelberg, Heidelberg., 33(6), 1481-1486.
https://doi.org/10.1007/s00296-012-2586-y

Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić S, Stanković B, Pavlović S. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International. 2013;33(6):1481-1486.
doi:10.1007/s00296-012-2586-y .

Jančić, Ivan, Arsenović-Ranin, Nevena, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Srzentić, Sanja, Stanković, Biljana, Pavlović, Sonja, "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis" in Rheumatology International, 33, no. 6 (2013):1481-1486,
https://doi.org/10.1007/s00296-012-2586-y . .

TY  - CONF
AU  - Arsenović-Ranin, Nevena
AU  - Jančić, Ivan
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, S.
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić, Sanja
AU  - Stanković, B.
AU  - Pavlović, S.
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1652
PB  - Wiley-Blackwell, Hoboken
C3  - Immunology
T1  - Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis
VL  - 137
SP  - 24
EP  - 24
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1652
ER  - 

@conference{
author = "Arsenović-Ranin, Nevena and Jančić, Ivan and Sefik-Bukilica, Mirjana and Živojinović, S. and Damjanov, Nemanja and Spasovski, Vesna and Srzentić, Sanja and Stanković, B. and Pavlović, S.",
year = "2012",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Immunology",
title = "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis",
volume = "137",
pages = "24-24",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1652"
}

Arsenović-Ranin, N., Jančić, I., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić, S., Stanković, B.,& Pavlović, S.. (2012). Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology
Wiley-Blackwell, Hoboken., 137, 24-24.
https://hdl.handle.net/21.15107/rcub_farfar_1652

Arsenović-Ranin N, Jančić I, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić S, Stanković B, Pavlović S. Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology. 2012;137:24-24.
https://hdl.handle.net/21.15107/rcub_farfar_1652 .

Arsenović-Ranin, Nevena, Jančić, Ivan, Sefik-Bukilica, Mirjana, Živojinović, S., Damjanov, Nemanja, Spasovski, Vesna, Srzentić, Sanja, Stanković, B., Pavlović, S., "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis" in Immunology, 137 (2012):24-24,
https://hdl.handle.net/21.15107/rcub_farfar_1652 .

TY  - JOUR
AU  - Perić, Aneta
AU  - Toskić-Radojičić, Marija
AU  - Dobrić, Silva
AU  - Damjanov, Nemanja
AU  - Miljković, Branislava
AU  - Antunović, Mirjana
AU  - Vezmar, Sandra
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1366
AB  - Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.
PB  - Wiley-Blackwell, Malden
T2  - Journal of Evaluation in Clinical Practice
T1  - Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?
VL  - 16
IS  - 6
SP  - 1090
EP  - 1095
DO  - 10.1111/j.1365-2753.2009.01258.x
ER  - 

@article{
author = "Perić, Aneta and Toskić-Radojičić, Marija and Dobrić, Silva and Damjanov, Nemanja and Miljković, Branislava and Antunović, Mirjana and Vezmar, Sandra",
year = "2010",
abstract = "Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was developed. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.",
publisher = "Wiley-Blackwell, Malden",
journal = "Journal of Evaluation in Clinical Practice",
title = "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?",
volume = "16",
number = "6",
pages = "1090-1095",
doi = "10.1111/j.1365-2753.2009.01258.x"
}

Perić, A., Toskić-Radojičić, M., Dobrić, S., Damjanov, N., Miljković, B., Antunović, M.,& Vezmar, S.. (2010). Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice
Wiley-Blackwell, Malden., 16(6), 1090-1095.
https://doi.org/10.1111/j.1365-2753.2009.01258.x

Perić A, Toskić-Radojičić M, Dobrić S, Damjanov N, Miljković B, Antunović M, Vezmar S. Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?. in Journal of Evaluation in Clinical Practice. 2010;16(6):1090-1095.
doi:10.1111/j.1365-2753.2009.01258.x .

Perić, Aneta, Toskić-Radojičić, Marija, Dobrić, Silva, Damjanov, Nemanja, Miljković, Branislava, Antunović, Mirjana, Vezmar, Sandra, "Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?" in Journal of Evaluation in Clinical Practice, 16, no. 6 (2010):1090-1095,
https://doi.org/10.1111/j.1365-2753.2009.01258.x . .